SCHEDULE OF REVENUE OF PRODUCTION AND DISTRIBUTION OF VENDORS (Details) - USD ($) |
12 Months Ended | |
|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Concentration Risk [Line Items] | ||
| Accounts payable | $ 44,318 | $ 55,092 |
| Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Vendor A [Member] | ||
| Concentration Risk [Line Items] | ||
| Direct Costs | $ 8,800 | |
| Concentration risk, percentage | 17.00% | |
| Revenue Benchmark [Member] | Supplier Concentration Risk [Member] | Vendor B [Member] | ||
| Concentration Risk [Line Items] | ||
| Direct Costs | $ 296,000 | |
| Concentration risk, percentage | 99.00% | |
| Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor A [Member] | ||
| Concentration Risk [Line Items] | ||
| Accounts payable | $ 4,400 | $ 8,800 |
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate direct operating costs incurred during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|